🍽️ fursultiamine hydrochloride non-drug

AI Engines For more Details: PerplexityKagi LabsYou

  1. Treatment of Thiamine Deficiency: Fursultiamine hydrochloride is primarily used to treat thiamine deficiency, which can occur due to inadequate dietary intake, malabsorption disorders, chronic alcoholism, or certain medical conditions. Thiamine deficiency can lead to symptoms such as fatigue, weakness, neurological problems, and cardiovascular abnormalities. Fursultiamine hydrochloride supplementation helps restore thiamine levels in the body and alleviates deficiency-related symptoms.

  2. Improved Energy Metabolism: Thiamine is essential for the metabolism of carbohydrates, fats, and proteins, playing a crucial role in cellular energy production. Fursultiamine hydrochloride supplementation can enhance energy metabolism by facilitating the conversion of nutrients into usable energy for various physiological processes. This may result in improved energy levels and overall well-being, particularly in individuals with thiamine deficiency.

  3. Neurological Benefits: Thiamine is important for proper neurological function, and thiamine deficiency can manifest as neurological symptoms such as neuropathy, weakness, and cognitive impairment. Fursultiamine hydrochloride supplementation helps maintain optimal thiamine levels in the nervous system, which may support nerve function and reduce the risk of neurological complications associated with thiamine deficiency.

  4. Cardiovascular Health: Thiamine plays a role in cardiovascular function, and thiamine deficiency can lead to heart-related complications such as congestive heart failure and cardiac arrhythmias. By replenishing thiamine levels, fursultiamine hydrochloride supplementation may support cardiovascular health and reduce the risk of heart-related complications in individuals with thiamine deficiency.

  5. Alleviation of Fatigue and Weakness: Thiamine deficiency can cause symptoms such as fatigue, weakness, and muscle pain due to impaired energy metabolism and neuromuscular function. Fursultiamine hydrochloride supplementation helps address these symptoms by restoring thiamine levels and improving cellular energy production, thereby promoting vitality and physical endurance.

  6. Treatment of Wernicke-Korsakoff Syndrome: Wernicke-Korsakoff syndrome is a neurological disorder caused by severe thiamine deficiency, often associated with chronic alcoholism. Fursultiamine hydrochloride may be used as part of the treatment regimen for Wernicke-Korsakoff syndrome to replenish thiamine levels and alleviate neurological symptoms.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of fursultiamine hydrochloride non-drug On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by fursultiamine hydrochloride non-drug

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Veillonella genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Bifidobacterium genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Akkermansia genus Decreases 📓 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Thomasclavelia ramosa species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Ruminococcus bromii species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Paraprevotella clara species Decreases ⚗️ Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Bacteroides caccae species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Akkermansia glycaniphila species Decreases 👶 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of fursultiamine hydrochloride non-drug on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 -0.3
ADHD 2.6 0.4 5.5
Age-Related Macular Degeneration and Glaucoma 0.5 0.5
Allergic Rhinitis (Hay Fever) 1 1.6 -0.6
Allergies 3.5 1.8 0.94
Allergy to milk products 0.8 0.4 1
Alopecia (Hair Loss) 1.2 1.2
Alzheimer's disease 1.7 2.4 -0.41
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.3 0.4 2.25
Ankylosing spondylitis 2.5 0.7 2.57
Anorexia Nervosa 1.1 -1.1
Antiphospholipid syndrome (APS) 1 1
Asthma 1.3 0.3 3.33
Atherosclerosis 0.9 1.1 -0.22
Atrial fibrillation 2 0.7 1.86
Autism 6 4.5 0.33
Barrett esophagus cancer 0.5 0.1 4
benign prostatic hyperplasia 0.1 0.1
Biofilm 0.9 0.9
Bipolar Disorder 0.4 1.1 -1.75
Brain Trauma 0.8 0.2 3
Cancer (General) 0.2 2.2 -10
Carcinoma 2.5 2 0.25
Celiac Disease 1.3 2.4 -0.85
Cerebral Palsy 1.2 0.7 0.71
Chronic Fatigue Syndrome 4.8 3.9 0.23
Chronic Kidney Disease 1.1 0.7 0.57
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.8 0.2 3
Chronic Urticaria (Hives) 1.1 0.3 2.67
Coagulation / Micro clot triggering bacteria 0.4 0.7 -0.75
Colorectal Cancer 1.5 0.8 0.88
Constipation 0.5 0.5 0
Coronary artery disease 1 0.9 0.11
COVID-19 8.7 8.2 0.06
Crohn's Disease 4.5 2.4 0.88
cystic fibrosis 0.3 0.5 -0.67
deep vein thrombosis 0.3 0.3 0
Depression 5.4 4.2 0.29
Dermatomyositis 0.1 0.3 -2
Eczema 0.9 1 -0.11
Endometriosis 1.7 0.8 1.13
Eosinophilic Esophagitis 0 0.4 0
Epilepsy 1.6 0.9 0.78
Fibromyalgia 1.9 1.5 0.27
Functional constipation / chronic idiopathic constipation 2.5 1.5 0.67
gallstone disease (gsd) 1.8 0.5 2.6
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.8 0.8 0
Generalized anxiety disorder 1.1 1.3 -0.18
giant cell arteritis 0.4 -0.4
Glioblastoma 0.1 -0.1
Gout 0.1 -0.1
Graves' disease 0.9 1.3 -0.44
Halitosis 0.6 0.1 5
Hashimoto's thyroiditis 1.5 0.4 2.75
Hidradenitis Suppurativa 0.1 0.4 -3
High Histamine/low DAO 1.4 0.4 2.5
hypercholesterolemia (High Cholesterol) 0.6 0.1 5
hyperglycemia 0.1 0.9 -8
Hyperlipidemia (High Blood Fats) 0.8 0.4 1
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 1.2 3.4 -1.83
Hypothyroidism 1.1 -1.1
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 2.3 -2.3
Inflammatory Bowel Disease 2.8 3.6 -0.29
Insomnia 0.6 0.2 2
Intelligence 0.7 0.2 2.5
Intracranial aneurysms 0.6 0.4 0.5
Irritable Bowel Syndrome 2.5 1.9 0.32
Liver Cirrhosis 2.8 2.1 0.33
Long COVID 5.1 6 -0.18
Low bone mineral density 0.2 -0.2
Lung Cancer 0.2 1 -4
Mast Cell Issues / mastitis 0.2 0.6 -2
ME/CFS with IBS 0.9 2.2 -1.44
ME/CFS without IBS 1.9 1.6 0.19
Menopause 1.5 1.5
Metabolic Syndrome 4.8 4.6 0.04
Mood Disorders 7.7 4.5 0.71
multiple chemical sensitivity [MCS] 0.7 0.4 0.75
Multiple Sclerosis 3 1.8 0.67
Multiple system atrophy (MSA) 0.5 0.8 -0.6
neuropathic pain 0.5 -0.5
Neuropathy (all types) 0.5 0.1 4
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.9 3.4 -0.79
NonCeliac Gluten Sensitivity 0.3 -0.3
Obesity 5.6 2.4 1.33
obsessive-compulsive disorder 3 2.3 0.3
Osteoarthritis 1.7 0.1 16
Osteoporosis 1.4 0.6 1.33
pancreatic cancer 0.3 0.3
Parkinson's Disease 1.6 1.6 0
Polycystic ovary syndrome 1.4 1.3 0.08
Postural orthostatic tachycardia syndrome 0.4 0.4 0
Premenstrual dysphoric disorder 1.1 1.1
primary biliary cholangitis 0.4 0.7 -0.75
Psoriasis 3.7 0.6 5.17
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.1 2.6 0.58
Rosacea 0.6 0.5 0.2
Schizophrenia 5.2 1.4 2.71
scoliosis 0.1 0.1 0
Sjögren syndrome 2.2 2.4 -0.09
Sleep Apnea 1 1 0
Slow gastric motility / Gastroparesis 0.9 0.3 2
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.4 -0.33
Stress / posttraumatic stress disorder 1.6 1.8 -0.13
Systemic Lupus Erythematosus 2.3 1.1 1.09
Tic Disorder 0.6 1.3 -1.17
Tourette syndrome 0 0.1 0
Type 1 Diabetes 1.9 1.7 0.12
Type 2 Diabetes 4.8 3.6 0.33
Ulcerative colitis 1.9 2.4 -0.26
Unhealthy Ageing 2.7 0.8 2.38

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]